Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To complete the production run of KAI-4169 in the first quarter of 2010
Subscribe to our email newsletter
Formatech has selected Kai Pharmaceuticals (Kai) and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program. Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010.
KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism. Under the program, Formatech is expected to donate the services required to aseptically fill and finish one lot of the drug product for use in support of Kai’s upcoming clinical trials.
Jeffrey Bernard, director of business development at Formatech, said: “We’re excited to have the opportunity to work with Kai on this program. Kai’s technology for developing selective Protein C Kinase inhibitors is very promising and has the potential to be very impactful in the treatment of a number of diseases. We’re pleased to donate our services for this program and we wish Kai success with this candidate.”
Steve James, president and CEO of Kai, said: “It is an honor to receive this award from Formatech as part of their philanthropic effort. We appreciate Formatech’s commitment to this program. This fill will help support our ‘4169 program and we look forward to exciting results in the year ahead.”